Sera Prognostics (NASDAQ:SERA) CFO Sells $11,531.10 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 6,069 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total transaction of $11,531.10. Following the completion of the sale, the chief financial officer directly owned 265,471 shares of the company’s stock, valued at approximately $504,394.90. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Austin Aerts also recently made the following trade(s):

• On Wednesday, March 11th, Austin Aerts sold 1,019 shares of Sera Prognostics stock. The shares were sold at an average price of $2.04, for a total transaction of $2,078.76.
• On Monday, March 9th, Austin Aerts sold 674 shares of Sera Prognostics stock. The stock was sold at an average price of $1.96, for a total transaction of $1,321.04.

Sera Prognostics Stock Up 7.0%

Shares of Sera Prognostics stock opened at $2.13 on Friday. Sera Prognostics, Inc. has a twelve month low of $1.37 and a twelve month high of $4.20. The company has a 50-day simple moving average of $2.74 and a two-hundred day simple moving average of $3.05. The stock has a market capitalization of $82.22 million, a price-to-earnings ratio of -2.77 and a beta of 1.01.

Key Stories Impacting Sera Prognostics

Here are the key news stories impacting Sera Prognostics this week:

• Positive Sentiment: Jefferies raised SERA to a “strong-buy” in mid‑December and the MarketBeat consensus target is about $5.00 — a bullish analyst view that can support price upside in thinly traded biotech names. MarketBeat Analyst Coverage
• Neutral Sentiment: A recent comparison piece contrasts Sera with peers (Revvity), which may increase investor attention and trading interest but contains no company-specific fundamental news. Contrasting Sera Prognostics (NASDAQ:SERA) and Revvity (NYSE:RVTY)
• Neutral Sentiment: Institutions own a meaningful portion of SERA (reported ~54.6%); continued institutional interest can provide a bid under the stock even as insiders sell. Institutional Ownership Details
• Negative Sentiment: CEO Zhenya Lindgardt sold 22,639 shares at ~$1.90 on Mar 10 and 2,973 shares at ~$2.04 on Mar 11 (total ~25,612 shares, ≈$49k), representing small but notable reductions in his holdings; concentrated CEO selling can weigh on sentiment in small‑cap biotechs. SEC Filing – Lindgardt Sales
• Negative Sentiment: CFO Austin Aerts sold a total of 7,088 shares across Mar 9–11 (6,069 at $1.90 and 1,019 at $2.04), reducing his stake ~2.2% in one filing; CFO sales can be read as liquidity‑taking and may cause short‑term pressure. InsiderTrades – Aerts Sales
• Negative Sentiment: Several other insiders (General Counsel Benjamin Jackson; John J. Boniface; Paul Kearney; Robert Gardner Harrison) sold small blocks on Mar 11 (combined ~4,656 shares, ≈$9.5k). The cluster of multiple insider sales in a short window can amplify negative investor interpretation. SEC Filings – Insider Sales

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new stake in Sera Prognostics in the fourth quarter valued at $31,000. Vanguard Personalized Indexing Management LLC bought a new stake in Sera Prognostics in the third quarter worth approximately $38,000. Riverview Capital Advisers LLC bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at $35,000. Lido Advisors LLC acquired a new position in shares of Sera Prognostics during the third quarter valued at about $68,000. Finally, Cetera Investment Advisers acquired a new position in Sera Prognostics during the 4th quarter worth approximately $74,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SERA has been the subject of a number of analyst reports. Jefferies Financial Group upgraded shares of Sera Prognostics to a “strong-buy” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.